Therapeutic compositions that produce an immune response

Details Therapeutic compositions that produce an immune response Therapeutic compositions that produce an immune response

2008-04-22

2008-04-22

Canella, Karen A. (Department: 1643)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S193100, C424S277100

Reexamination Certificate

active

09152698

ABSTRACT:
The invention provides a method for stimulating the production of antibodies to a cryptic epitope on a soluble antigen by administering to a patient having such a cryptic epitope a binding agent that binds to the soluble antigen and forming a complex between the binding agent and the soluble antigen, wherein the cryptic epitope is exposed and the patient generates antibodies that bind to the cryptic epitope.

REFERENCES:
patent: 4740371 (1988-04-01), St.Remy et al.
patent: 4879225 (1989-11-01), Morgan, Jr. et al.
patent: 5053224 (1991-10-01), Koprowski et al.
patent: 5240833 (1993-08-01), Nudelman
patent: 5512283 (1996-04-01), Byers et al.
patent: 5583202 (1996-12-01), Zanetti et al.
patent: 5591593 (1997-01-01), Courtenay-Luck
patent: 5652114 (1997-07-01), Chu et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5807978 (1998-09-01), Kokolus
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5976818 (1999-11-01), O'Brien
patent: 6068830 (2000-05-01), Diamandis et al.
patent: 6077519 (2000-06-01), Storkus et al.
patent: 6088613 (2000-07-01), Unger
patent: 6096289 (2000-08-01), Goldenberg
patent: 6140091 (2000-10-01), Raso et al.
patent: 0 153 871 (1985-09-01), None
patent: WO 93/20185 (1993-10-01), None
patent: WO 94/21287 (1994-09-01), None
patent: WO95/04548 (1995-02-01), None
patent: WO98/57661 (1998-12-01), None
patent: WO 99/65517 (1999-12-01), None
Clark, Protein Engineering of antibody Molecules for Prophylactic and therapeutic Applications in Man, (monograph), 1993, p. 1.
Chattopadhyay et al, Cancer Research, 1991, vol. 51, pp. 6045-6051.
Rooijen, Res Immunol, 1993, vol. 144, pp. 545-552.
Klaus, Nature, 1978, vol. 272, pp. 265-266.
Tassi et al, Immunology Letters, 1991, vol. 27, pp. 39-44.
Frodin et al, Hybridoma, 1991, vol. 10, pp. 421-431. (abstract).
Fagerberg et al, Cancer Immunol Immunother, 1996, vol. 42, pp. 81-87. (abstract).
Herbert, Dictionary of Immunology, p. 79.
Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., 1991, pp. 105-107.
Baum et al (Cancer, 1994, vol. 73 (3 suppl), pp. 1121-1125).
Wagner et al (Biotechnology Therapeutics, 1992, vol. 3, pp. 81-89).
Schwartz, (“Cancer Markers”, In: Cancer: Principles and Practice of Clinical Oncology, 4th Edition, 1994, DeVita et al, Ed.s., p. 531-542).
Goldenberg et al (“Cancer Diagnosis and Therapy with Radiolabeled Antibodies”, In: Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer, Vogel. Ed., 1987, pp. 259-280).
The abstract of Bachmann et al (European Journal of Immunology, 1994, vol. 24, pp. 2567-2570).
The abstract of Yin et al (International Journal of Cancer, 1996, vol. 65, pp. 406-412).
The abstract of McGuckin et al (Clinica Chimica Acta, 1993, vol. 214, pp. 139-151).
Kedar et al (‘Cancer Immunotherapy’ In: Advances in CanceR Research, 1992, vol. 59, pp. 245-323).
Crowley et al (Journal of Experiemtnal Medicine, 1990, vol. 172, pp. 383-386).
Sallusto et al (Journal of Experiemntal Medicine, 1994, vol. 179, pp. 1109-1118.
de La Salle et al (‘FcgR on Humna Dendritic Cells’ In:Human IgG Receptors, 1996, pp. 39-55, Van de winkel et al Eds).
Dong et al (In: VAccine Desgin: The Subunit Approach, Powell et al, Ed., 1995, pp. 625-643).
Vrba et al (PNAS, 1975, vol. 72, pp. 4602-4606).
Paul (Fundamental Immunology, (text), 1993, p. 1163).
The abstract of Jurncic-Winkler et al (Eur Urol, 1993, vol. 24, pp. 487-491).
Simitsek et al (J Exp Med, 1995, vol. 181, pp. 1957-1963).
Nishimura et al, Cancer Chemother Pharmacol, 2000, vol. 46, suppl. pp. S52-S61.
Watts et al, J Exp Med, 1993, vol. 178, pp. 1495-1463.
Cibotti et al PNAS, 1992, vol. 89, pp. 416-420.
Abstract of Pani et al (Immunological Investigations, 1994, vol. 23, pp. 337-346).
Benichou et al, 1994, vol. 6, pp. 131-138.
Lee et al, Journal of Immunology, 1999, vol. 163, pp. 6292-6300).
Ohlen et al (Journal of Immunology, 2001, vol. 166, pp. 2863-2870).
Antonia et al (International Immunology, 1995, vol. 7, pp. 715-725).
Paul, Fundamental Immunology, (text), 1993, pp. 1163-1169.
Abstract of Semino et al (Journal of Biological Regulators and Homeostatic Agents, 1993, vol. 7, pp. 99-105.
Abstract of Algarra et al, International Journal of Clinical and Laboratory Research, 1997, vol. 27, pp. 95-102.
Bodey et al (Anticancer Research, Jul.-Aug. 2000, vol. 20, pp. 2665-2676.
PCT International Search Report Corresponding To PCT International Application No. PCT/IB99/01114; Authorized Officer: M. Covone: Date of Completion: Nov. 30, 1999; Date of Mailing: Dec. 15, 1999 (8 pages).
Madiyalakan, R. et al., HYBRIDOMA, vol. 14, No. 2, 1995, “Antiidotype Induction Therapy: Evidence for the induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA125 Murine Monoclonal Antibody B43.13”, pp. 199-203.
Leveugle, B. et al., Proceedings of the American Associate for Cancer Research Annual Meeting, vol. 39, Mar. 1998, “PSA-directed immunotherapy of prostate cancer.”, p. 355, (1 page).
Foon, K.A. et al., Clinical Cancer Research, vol. 3, Aug. 1997, “Clinical and Immune Responses in Advanced Colorectal Cancer Patients Treated with Anti-Idiotype Monoclonal Antibody Vaccine That Mimics the Carcinoembryonic Antigen”, pp. 1267-1276.
Uemura, H. et al., Jpn J. Cancer Res., vol. 7, No. 10, 1995, “Generation of anti-idiotype antibodies related to prostatic specific antigen” (meeting abstract), p. 427.
Schultes, B.C. et al., Cancer Immunol Immunother, vol. 46, No. 4, Jun. 1998, “Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)”, pp. 201-212.
Baum, 1994, Activating Anti-Idiotypic Human Anti-Mouse Antobodies for Immunotherapy of Ovarian Carcinoma, Cancer 73:1121-1125.
Golumbek et al., 1993, The Antitumor Immune-Response as a Problem of Self-NonSelf Discrimination—Implications for Immunotherapy, Immunologic Res. 12:183-192 (Abstract only).
Jacobs and Haskell, 1991, Clinical Use of Tumor Markers in Oncology, Curr. Probl Cancer 15(6):299-360.
Lanzavecchia, 1996, Mechanisms of antigen uptake for presentation, Curr. Opin. Imm. 8:348-354.
Leitzel et al., 1992, Elevated Soluble c-erbB-2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients, J. Clin. Oncol. 10(9):1436-1443.
Madiyalakan et al., 1997, OVAREX™ Mab-B43.13:IFN-y Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cells, Hybridoma 16:41-45.
Wagner et al., 1992, Immunotherapy of Advanced Ovarian Carcinomas by Activation of the Idiotypic Network, Biotech. Ther. 3:81-89.
Ward et al., 1997, Unconjugated antibodies for cancer therapy: lessons from the clinic, Cancer Treatment Rev. 23:305-319.
Schultze et al., “DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.” Trends in Immunology 25:659-664, (2004).

Affiliated with

Also associated with

Rating

Therapeutic compositions that produce an immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic compositions that produce an immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions that produce an immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3954622